Cite
HARVARD Citation
Robson, M. et al. (2023). OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European journal of cancer. pp. 39-47. [Online].